Stage III/IV melanoma patients at risk for new primaries
(HealthDay)—Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas (NPMs), although the incidence rates are lower than those observed ...
Dec 10, 2013
0
0